HM16390

· Hanmi Pharmaceutical Company Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HM16390, covering 2025-12-17 to 2025-12-17. Get the full timeline:

Most recent: Clinical Trial Update: Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors [Phase 1]

See pricing